{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T14:06:59Z","timestamp":1784038019422,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Australian National Health and Medical Research Council","award":["APP1078345"],"award-info":[{"award-number":["APP1078345"]}]},{"name":"Curtin University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anticholinergic burden scales are widely used to guide medication review in older adults, yet their ability to predict clinically important adverse outcomes remains uncertain, as most evidence is based on associations rather than validated risk prediction. In the absence of a gold standard, the clinical value of these scales depends on whether they can discriminate between individuals at risk and provide accurate absolute risk estimates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare the predictive performance of six anticholinergic burden scales for hospitalisation\/emergency department (ED) visits related to anticholinergic adverse effects, assess internal and temporal validation of cognitive impairment models across scales, and examine the risk gradient across increasing anticholinergic burden levels for cognitive impairment across scales.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A retrospective cohort study using linked population-level administrative health data of adults aged\u2009\u2265\u200965 years in Western Australia (2015\u20132019). Development cohorts were from 2015\u201316 (N\u2009=\u2009323,682) and 2016\u201317 (N\u2009=\u2009334,304), and the temporal validation cohort was from 2017\u201318 (N\u2009=\u2009330,684). Six anticholinergic burden scales were calculated annually. Logistic regression models with common predictor structure including demographic and clinical predictors were used to predict any hospitalisation\/ED visit related to anticholinergic adverse events (falls\/fractures\/dizziness, cognitive impairment, or constipation\/urinary retention). Model performance was assessed using the c-statistic, calibration slope, and Brier score. Cognitive impairment models were further evaluated using bootstrap internal validation (200 replications), temporal validation, and predicted risk estimation across exposure deciles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across initial model comparisons, Korean Anticholinergic Burden Scale (KABS) showed the highest c-statistics for each outcome, although between-scale differences were small. Cognitive impairment showed the highest discrimination across scales and was selected for further validation. In temporal validation, c-statistics for cognitive impairment ranged from 0.795 to 0.806, with the highest value observed for KABS, and calibration slopes ranging from 1.024 to 1.032 across scales. Predicted risk of cognitive impairment increased across exposure deciles for all scales, with the highest-decile risk ranging from 5.27% for TSDD-SAMS to 7.58% for KABS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KABS showed slightly higher and more consistent predictive performance than the other scales, particularly for cognitive impairment, although between-scale differences were modest. Presenting validated absolute risk estimates across exposure groups may improve clinical interpretability and support risk stratification, but wider validation and clinical judgement remain essential before routine use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02145-9","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:57:55Z","timestamp":1776423475000},"page":"1646-1659","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative predictive performance of anticholinergic burden scales for anticholinergic-related hospitalisation and emergency department visits in older adults: a population-based study of model development and temporal validation"],"prefix":"10.1007","volume":"48","author":[{"given":"Valentina M.","family":"Srikartika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Youens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Moorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninh","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"2145_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18773\/austprescr.2022.031","volume":"45","author":"SN Hilmer","year":"2022","unstructured":"Hilmer SN, Gnjidic D. The anticholinergic burden: from research to practice. Aust Prescr. 2022;45:118\u201320. https:\/\/doi.org\/10.18773\/austprescr.2022.031.","journal-title":"Aust Prescr"},{"key":"2145_CR2","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1038\/s41598-020-65989-9","volume":"10","author":"N Cebron Lipovec","year":"2020","unstructured":"Cebron Lipovec N, Jazbar J, Kos M. Anticholinergic burden in children, adults and older adults in Slovenia: a nationwide database study. Sci Rep. 2020;10:9337. https:\/\/doi.org\/10.1038\/s41598-020-65989-9.","journal-title":"Sci Rep"},{"key":"2145_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afad136","author":"V-L Cheong","year":"2023","unstructured":"Cheong V-L, Mehdizadeh D, Todd OM, et al. The extent of anticholinergic burden across an older Welsh population living with frailty: cross-sectional analysis of general practice records. Age Ageing. 2023. https:\/\/doi.org\/10.1093\/ageing\/afad136.","journal-title":"Age Ageing"},{"key":"2145_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12877-020-01657-x","volume":"20","author":"CM Grossi","year":"2020","unstructured":"Grossi CM, Richardson K, Savva GM, et al. Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive function and ageing study I and II. BMC Geriatr. 2020;20:267. https:\/\/doi.org\/10.1186\/s12877-020-01657-x.","journal-title":"BMC Geriatr"},{"key":"2145_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/jgs.19324","volume":"73","author":"T Novais","year":"2025","unstructured":"Novais T, Garnier-Crussard A, Reallon E, et al. Assessing the prevalence of anticholinergic and sedative medications to avoid in older adults from the French Health Data System. J Am Geriatr Soc. 2025;73:1542\u201350. https:\/\/doi.org\/10.1111\/jgs.19324.","journal-title":"J Am Geriatr Soc"},{"key":"2145_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015196.pub2","author":"M Taylor-Rowan","year":"2022","unstructured":"Taylor-Rowan M, Kraia O, Kolliopoulou C, et al. Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD015196.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"2145_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40266-020-00806-6","volume":"37","author":"J Reinold","year":"2020","unstructured":"Reinold J, Sch\u00e4fer W, Christianson L, et al. Anticholinergic burden and fractures: a systematic review with methodological appraisal. Drugs Aging. 2020;37:885\u201397. https:\/\/doi.org\/10.1007\/s40266-020-00806-6.","journal-title":"Drugs Aging"},{"key":"2145_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/20420986211016645","author":"C Stewart","year":"2021","unstructured":"Stewart C, Taylor-Rowan M, Soiza RL, et al. Anticholinergic burden measures and older people\u2019s falls risk: a systematic prognostic review. Therapeutic Adv Drug Saf. 2021. https:\/\/doi.org\/10.1177\/20420986211016645.","journal-title":"Therapeutic Adv Drug Saf"},{"key":"2145_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/bcpt.13692","volume":"130","author":"A Lisibach","year":"2022","unstructured":"Lisibach A, Gallucci G, Beeler PE, et al. High anticholinergic burden at admission associated with in-hospital mortality in older patients: a comparison of 19 different anticholinergic burden scales. Basic Clin Pharmacol Toxicol. 2022;130:288\u2013300. https:\/\/doi.org\/10.1111\/bcpt.13692.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2145_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/alz.071322","volume":"19","author":"KA Wyman-Chick","year":"2023","unstructured":"Wyman-Chick KA, Chrenka EA, Miller MJ, et al. The complex relationship between anticholinergic medication, frailty, and hospitalization in patients with early-stage dementia. Alzheimers Dement. 2023;19:e071322. https:\/\/doi.org\/10.1002\/alz.071322.","journal-title":"Alzheimers Dement"},{"key":"2145_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2024.105646","volume":"129","author":"VM Srikartika","year":"2025","unstructured":"Srikartika VM, Ha N, Youens D, et al. Assessing the feasibility of anticholinergic burden scales and measures in administrative data: a systematic review. Arch Gerontol Geriatr. 2025;129:105646. https:\/\/doi.org\/10.1016\/j.archger.2024.105646.","journal-title":"Arch Gerontol Geriatr"},{"key":"2145_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1370\/afm.2131","volume":"15","author":"W-H Hsu","year":"2017","unstructured":"Hsu W-H, Wen Y-W, Chen L-K, et al. Comparative associations between measures of anti-cholinergic burden and adverse clinical outcomes. Annals Family Med. 2017;15:561\u20139. https:\/\/doi.org\/10.1370\/afm.2131.","journal-title":"Annals Family Med"},{"key":"2145_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40266-012-0044-x","volume":"30","author":"L Pasina","year":"2013","unstructured":"Pasina L, Djade CD, Lucca U, et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale. Drugs Aging. 2013;30:103\u201312. https:\/\/doi.org\/10.1007\/s40266-012-0044-x.","journal-title":"Drugs Aging"},{"key":"2145_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40360-020-00467-6","volume":"22","author":"S Hwang","year":"2021","unstructured":"Hwang S, Chung JE, Jun K, et al. Comparative associations between anticholinergic burden and emergency department visits for anticholinergic adverse events in older Korean adults: a nested case-control study using national claims data for validation of a novel country-specific scale. BMC Pharmacol Toxicol. 2021;22:2. https:\/\/doi.org\/10.1186\/s40360-020-00467-6.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2145_CR15","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/m14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1-73. https:\/\/doi.org\/10.7326\/m14-0698.","journal-title":"Ann Intern Med"},{"key":"2145_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128\u201338. https:\/\/doi.org\/10.1097\/EDE.0b013e3181c30fb2.","journal-title":"Epidemiology"},{"key":"2145_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.2017.12126","volume":"318","author":"AC Alba","year":"2017","unstructured":"Alba AC, Agoritsas T, Walsh M, et al. Discrimination and calibration of clinical prediction models: users\u2019 guides to the medical literature. JAMA. 2017;318:1377\u201384. https:\/\/doi.org\/10.1001\/jama.2017.12126.","journal-title":"JAMA"},{"key":"2145_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s40266-024-01159-0","volume":"41","author":"C Ge\u00dfele","year":"2024","unstructured":"Ge\u00dfele C, R\u00e9mi C, Smolka V, et al. Anticholinergic exposure, drug dose and postoperative delirium: comparison of dose-related and non-dose-related anticholinergic burden scores in a retrospective cohort study of older orthopaedic and trauma surgery patients. Drugs Aging. 2024;41:1003\u201313. https:\/\/doi.org\/10.1007\/s40266-024-01159-0.","journal-title":"Drugs Aging"},{"key":"2145_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11096-020-01117-x","volume":"43","author":"M Lavrador","year":"2021","unstructured":"Lavrador M, Cabral AC, Figueiredo IV, et al. Size of the associations between anticholinergic burden tool scores and adverse outcomes in older patients. Int J Clin Pharm. 2021;43:128\u201336. https:\/\/doi.org\/10.1007\/s11096-020-01117-x.","journal-title":"Int J Clin Pharm"},{"key":"2145_CR20","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1111\/bcp.16123","volume":"90","author":"GO Phutietsile","year":"2024","unstructured":"Phutietsile GO, Fotaki N, Nishtala PS. Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties. Br J Clin Pharmacol. 2024;90:2236\u201355. https:\/\/doi.org\/10.1111\/bcp.16123.","journal-title":"Br J Clin Pharmacol"},{"key":"2145_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","volume":"168","author":"JL Rudolph","year":"2008","unstructured":"Rudolph JL, Salow MJ, Angelini MC. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508\u201313. https:\/\/doi.org\/10.1001\/archinternmed.2007.106.","journal-title":"Arch Intern Med"},{"key":"2145_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123357","author":"\u00c1 Tristancho-P\u00e9rez","year":"2022","unstructured":"Tristancho-P\u00e9rez \u00c1, Villalba-Moreno \u00c1, L\u00f3pez-Malo de Molina MD, et al. The predictive value of anticholinergic burden measures in relation to cognitive impairment in older chronic complex patients. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11123357.","journal-title":"J Clin Med"},{"key":"2145_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280907","volume":"18","author":"TS Dinh","year":"2023","unstructured":"Dinh TS, Meid AD, Rudolf H, et al. Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: development and validation of a prognostic model. PLoS ONE. 2023;18:e0280907. https:\/\/doi.org\/10.1371\/journal.pone.0280907.","journal-title":"PLoS ONE"},{"key":"2145_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40273-014-0224-0","volume":"33","author":"E Onukwugha","year":"2015","unstructured":"Onukwugha E, Bergtold J, Jain R. A primer on marginal effects-Part II: health services research applications. Pharmacoeconomics. 2015;33:97\u2013103. https:\/\/doi.org\/10.1007\/s40273-014-0224-0.","journal-title":"Pharmacoeconomics"},{"key":"2145_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jbi.2013.12.003","volume":"50","author":"SM Randall","year":"2014","unstructured":"Randall SM, Ferrante AM, Boyd JH, et al. Privacy-preserving record linkage on large real world datasets. J Biomed Inform. 2014;50:205\u201312. https:\/\/doi.org\/10.1016\/j.jbi.2013.12.003.","journal-title":"J Biomed Inform"},{"key":"2145_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1467-842x.1999.tb01297.x","volume":"23","author":"CD Holman","year":"1999","unstructured":"Holman CD, Bass AJ, Rouse IL, et al. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health. 1999;23:453\u20139. https:\/\/doi.org\/10.1111\/j.1467-842x.1999.tb01297.x.","journal-title":"Aust N Z J Public Health"},{"key":"2145_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022500","volume":"8","author":"CJ Byrne","year":"2018","unstructured":"Byrne CJ, Walsh C, Cahir C, et al. Anticholinergic and sedative drug burden in community-dwelling older people: a national database study. BMJ Open. 2018;8:e022500. https:\/\/doi.org\/10.1136\/bmjopen-2018-022500.","journal-title":"BMJ Open"},{"key":"2145_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bcpt.13184","volume":"124","author":"YM Ah","year":"2019","unstructured":"Ah YM, Suh Y, Jun K, et al. Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic Clin Pharmacol Toxicol. 2019;124:741\u20138. https:\/\/doi.org\/10.1111\/bcpt.13184.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2145_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2019.103912","volume":"85","author":"S Hwang","year":"2019","unstructured":"Hwang S, Jun K, Ah Y-M, et al. Impact of anticholinergic burden on emergency department visits among older adults in Korea: a national population cohort study. Arch Gerontol Geriatr. 2019;85:103912. https:\/\/doi.org\/10.1016\/j.archger.2019.103912.","journal-title":"Arch Gerontol Geriatr"},{"key":"2145_CR30","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","volume":"179","author":"CAC Coupland","year":"2019","unstructured":"Coupland CAC, Hill T, Dening T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179:1084\u201393. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0677.","journal-title":"JAMA Intern Med"},{"key":"2145_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401\u20137. https:\/\/doi.org\/10.1001\/jamainternmed.2014.7663.","journal-title":"JAMA Intern Med"},{"key":"2145_CR32","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/ggi.13680","volume":"19","author":"K Jun","year":"2019","unstructured":"Jun K, Hwang S, Ah Y-M, et al. Development of an anticholinergic burden scale specific for Korean older adults. Geriatr Gerontol Int. 2019;19:628\u201334. https:\/\/doi.org\/10.1111\/ggi.13680.","journal-title":"Geriatr Gerontol Int"},{"key":"2145_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1136757","volume":"14","author":"B Katzenberger","year":"2023","unstructured":"Katzenberger B, Koller D, Strobl R, et al. Exposure to anticholinergic and sedative medication is associated with impaired functioning in older people with vertigo, dizziness and balance disorders-results from the longitudinal multicenter study MobilE-TRA. Front Pharmacol. 2023;14:1136757. https:\/\/doi.org\/10.3389\/fphar.2023.1136757.","journal-title":"Front Pharmacol"},{"key":"2145_CR34","unstructured":"National Health Service. Medication Safety \u2013 Indicators Spesifications. National Health Service Business Services Authority. 2019. https:\/\/www.nhsbsa.nhs.uk\/sites\/default\/files\/2018-12\/Medication%20Safety%20-%20Indicators%20SpecificationV2.2.pdf. Accessed 13 December 2025."},{"key":"2145_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-021-00213-y","volume":"7","author":"Y Ogawa","year":"2021","unstructured":"Ogawa Y, Hirai T, Mihara K. A meta-analysis of observational studies on anticholinergic burden and fracture risk: evaluation of conventional burden scales. J Pharm Health Care Sci. 2021;7:30. https:\/\/doi.org\/10.1186\/s40780-021-00213-y.","journal-title":"J Pharm Health Care Sci"},{"key":"2145_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40266-019-00731-3","volume":"37","author":"MP Tan","year":"2020","unstructured":"Tan MP, Tan GJ, Mat S, et al. Use of medications with anticholinergic properties and the long-term risk of hospitalization for falls and fractures in the EPIC-Norfolk longitudinal cohort study. Drugs Aging. 2020;37:105\u201314. https:\/\/doi.org\/10.1007\/s40266-019-00731-3.","journal-title":"Drugs Aging"},{"key":"2145_CR37","doi-asserted-by":"publisher","first-page":"S574","DOI":"10.21037\/jtd.2019.01.25","volume":"11","author":"ME Shipe","year":"2019","unstructured":"Shipe ME, Deppen SA, Farjah F, et al. Developing prediction models for clinical use using logistic regression: an overview. J Thorac Dis. 2019;11:S574\u201384. https:\/\/doi.org\/10.21037\/jtd.2019.01.25.","journal-title":"J Thorac Dis"},{"key":"2145_CR38","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","volume":"35","author":"EW Steyerberg","year":"2014","unstructured":"Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35:1925\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehu207.","journal-title":"Eur Heart J"},{"key":"2145_CR39","unstructured":"Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia. 2016. https:\/\/www.abs.gov.au\/ausstats\/abs@.nsf\/mf\/2033.0.55.001. Accessed 23 July 2024."},{"key":"2145_CR40","unstructured":"Australian Institute of Health and Welfare. Rural, regional and remote health: a guide to remoteness classifications. 2004. https:\/\/www.aihw.gov.au\/reports\/rural-remote-australians\/guide-to-remoteness-classifications\/formats. Accessed 23 July 2024."},{"key":"2145_CR41","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2005.01.020","volume":"58","author":"CD Holman","year":"2005","unstructured":"Holman CD, Preen DB, Baynham NJ, et al. A multipurpose comorbidity scoring system performed better than the Charlson index. J Clin Epidemiol. 2005;58:1006\u201314. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.01.020.","journal-title":"J Clin Epidemiol"},{"key":"2145_CR42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/heartjnl-2011-301246","volume":"98","author":"KG Moons","year":"2012","unstructured":"Moons KG, Kengne AP, Woodward M, et al. Risk prediction models: I. development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012;98:683\u201390. https:\/\/doi.org\/10.1136\/heartjnl-2011-301246.","journal-title":"Heart"},{"key":"2145_CR43","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2023","unstructured":"StataCorp. Stata statistical software: release 18. College Station, TX: StataCorp LLC; 2023."},{"key":"2145_CR44","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s11096-023-01566-0","volume":"45","author":"AE Schulthess-Lisibach","year":"2023","unstructured":"Schulthess-Lisibach AE, Gallucci G, Benelli V, et al. Predicting delirium in older non-intensive care unit inpatients: development and validation of the DELIrium risK Tool (DELIKT). Int J Clin Pharm. 2023;45:1118\u201327. https:\/\/doi.org\/10.1007\/s11096-023-01566-0.","journal-title":"Int J Clin Pharm"},{"key":"2145_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/0471722146.ch5","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2000","unstructured":"Hosmer DW, Lemeshow S. Assessing the fit of the model. In: Applied logistic regression. Second ed. New York: John Wiley & Sons, Inc; 2000. p. 143\u2013202.","edition":"Second ed"},{"key":"2145_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.euroneuro.2023.08.502","volume":"77","author":"N Vidal","year":"2023","unstructured":"Vidal N, Brunet-Gouet E, Frileux S, et al. Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: results from the FACE-BD cohort. Eur Neuropsychopharmacol. 2023;77:67\u201379. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.08.502.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2145_CR47","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1111\/bcp.15432","volume":"88","author":"A Lisibach","year":"2022","unstructured":"Lisibach A, Gallucci G, Benelli V, et al. Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients - a cohort study comparing 19 anticholinergic burden scales. Br J Clin Pharmacol. 2022;88:4915\u201327. https:\/\/doi.org\/10.1111\/bcp.15432.","journal-title":"Br J Clin Pharmacol"},{"key":"2145_CR48","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jamda.2016.07.012","volume":"17","author":"DL Vetrano","year":"2016","unstructured":"Vetrano DL, La Carpia D, Grande G, et al. Anticholinergic medication burden and 5-year risk of hospitalization and death in nursing home elderly residents with coronary artery disease. J Am Med Dir Assoc. 2016;17:1056\u20139. https:\/\/doi.org\/10.1016\/j.jamda.2016.07.012.","journal-title":"J Am Med Dir Assoc"},{"key":"2145_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01614-w","author":"M Schechner","year":"2025","unstructured":"Schechner M, Rottenkolber M, Weglage C, et al. Implied ADR-admissions: a cohort study introducing a novel administrative data approach for identifying drug-related hospitalisations. Drug Saf. 2025. https:\/\/doi.org\/10.1007\/s40264-025-01614-w.","journal-title":"Drug Saf"},{"key":"2145_CR50","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.16262","volume":"11","author":"YY Chou","year":"2023","unstructured":"Chou YY, Lee YS, Lin CS, et al. Gender-specific linkages: frailty, polypharmacy, anti-cholinergic burden, and 5-year mortality risk-a real-world analysis. PeerJ. 2023;11:e16262. https:\/\/doi.org\/10.7717\/peerj.16262.","journal-title":"PeerJ"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02145-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:31:02Z","timestamp":1784035862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02145-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02145-9","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Australian Institute of Health and Welfare, the Western Australia Department of Health, and Curtin University Human Research Ethics Committees (Approval number: HRE2024-0695).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}